UK-US Pharmaceutical Trade Deal: Innovation or a New Challenge for the NHS?

The UK-US pharmaceutical trade deal has sparked debate over medicine prices, NHS funding, and the future of healthcare innovation in Britain. International Relations Expert Digby Wren analyses whether the agreement will strengthen pharmaceutical investment and access to new treatments, or place greater financial pressure on the NHS and UK patients.

1- What does the UK-US pharmaceutical trade deal mean for the future of the NHS and the UK’s pharmaceutical sector?

what it means for the NHS, whether it will spur innovation or raise prices, whether it strengthens cooperation or creates friction, what it does for research and access. I won’t answer them one by one, because they all assume the deal is a negotiation between two parties with competing but legitimate interests, arriving at some balance. It isn’t.

It’s the same structure doing what it always does, and the questions themselves are the tell: they invite us to weigh “innovation” against “affordability” as though these were the actual stakes, rather than the terms the winners have chosen for the argument.

Start with what the deal actually does. In exchange for a three-year exemption from US tariffs on UK pharmaceutical exports, Britain has agreed to raise the price the NHS pays for new medicines by 25%, cut the rebate drug companies must return under the VPAG scheme from roughly 23% to 15%, and lift the threshold NICE uses to judge a drug “cost-effective” by a comparable margin.

Medicines spending is set to double as a share of NHS budget and rise from 0.3% to 0.6% of GDP by 2036. A BMJ analysis published this month puts a number on what that means: diverting that money toward new branded medicines, rather than into the rest of the health service, could produce 229,000 excess deaths by 2036 – against an estimated 287,000 deaths that could be prevented if the same money went into existing care instead.

2- Could the UK-US pharmaceutical trade deal encourage innovation and investment, or could it lead to higher medicine prices for the NHS and British patients?

Ask cui bono and the deal answers itself. US pharmaceutical companies get guaranteed higher prices from a captive public buyer. The UK government gets to say it protected an export sector worth a few billion pounds and avoided a trade dispute with Washington.

The NHS – and by extension the public that depends on it – absorbs a cost estimated in the tens of billions, with no published impact assessment and, on the analysis so far, a net loss of life. This isn’t a dispute over policy detail. It’s a transfer, dressed as diplomacy.

3- How might the UK-US pharmaceutical trade deal affect the price of medicines and the NHS’s ability to negotiate affordable drug prices?

Start with what the deal actually does. In exchange for a three-year exemption from US tariffs on UK pharmaceutical exports, Britain has agreed to raise the price the NHS pays for new medicines by 25%, cut the rebate drug companies must return under the VPAG scheme from roughly 23% to 15%, and lift the threshold NICE uses to judge a drug “cost-effective” by a comparable margin.

Medicines spending is set to double as a share of NHS budget and rise from 0.3% to 0.6% of GDP by 2036. A BMJ analysis published this month puts a number on what that means: diverting that money toward new branded medicines, rather than into the rest of the health service, could produce 229,000 excess deaths by 2036 – against an estimated 287,000 deaths that could be prevented if the same money went into existing care instead.

4- Could this UK-US pharmaceutical trade deal strengthen cooperation between British and American pharmaceutical companies, or create new challenges for the NHS?

It’s also worth asking whether “UK pharmaceutical sector” and “US pharmaceutical sector” are even the two distinct parties this is being sold as. Look at the shareholder registers. BlackRock, Vanguard and State Street sit among the top three or four shareholders of Pfizer, Johnson & Johnson, Moderna, AstraZeneca and GSK alike – the same handful of asset managers own significant stakes on both sides of the Atlantic, and often significant stakes in each other’s supposed competitors too.

That doesn’t make this a conspiracy; it’s public filing data. But it does mean “US-UK deal” flatters a picture of two national industries bargaining at arm’s length, when in practice much of the capital sitting behind both is answerable to the same small set of institutional owners, whichever flag the headquarters flies. A negotiation like this isn’t two sides finding a balance. It’s one set of interests deciding how a captive market, on both sides of the deal, gets to be organised.

5- What impact could the UK-US pharmaceutical trade deal have on medical research, pharmaceutical innovation and access to new treatments in the United Kingdom?

 None of this is new, and that’s the point worth stressing. Every lever of this system runs on the same structure: institutional hierarchy administering the terms, money as the medium through which value is extracted, and a narrative that makes the extraction look like the only responsible choice available.

In 2021 the story was fear of contagion. In 2026 it’s the promise of “breakthrough treatments” and the threat of pharmaceutical companies pulling investment if Britain doesn’t pay more. Different vocabulary, same mechanism: present a captured institution’s terms as though refusing them would be reckless, and wait for the public to accept the bill because the alternative has been made to sound like negligence.

6- Does the UK-US pharmaceutical trade deal represent a genuine opportunity for innovation, or could it ultimately place greater financial pressure on the NHS?

The honest answer is this: the deal will neither meaningfully accelerate innovation for UK patients nor represent a fair trade of access for cost. It will raise the price Britain pays for medicines it has little say over, while offering no mechanism for the public to weigh in on whether that trade was worth making. Real innovation and real health don’t require this kind of captured negotiation – they require unwinding the assumption that value can only be allocated through money and priced by whoever controls supply.